Assembly Biosciences presents interim data from ABI-H0731 Phase 1a, 1b studies
Assembly Biosciences presented interim results from Phase 1a and 1b study of ABI-H0731, a novel antiviral in development for the treatment of chronic HBV infection, in a "late-breaker" poster presentation at The International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver, or EASL. A copy of the poster can be found at assemblybio.com on the "Events & Presentations" page under "Investors." The late-breaker poster outlines interim data from the ongoing Phase 1b antiviral efficacy study and a recently completed Phase 1a safety and pharmacokinetic, or PK, study of ABI-H0731, a novel, oral Core protein Allosteric Modifier, or CpAM, with selective and potent activity against all major HBV genotypes. To date, two cohorts of HBV patients have completed dosing in the Phase 1b trial, in addition to three additional cohorts in a Phase 1a study in healthy volunteers. A third HBV patient cohort receiving 300 mg is ongoing, though only initial results are reported. Two HBeAg negative patients have also been treated at 400 mg.